NEW YORK, June 20, 2017 /PRNewswire/ --
If you want a stock review on VWR, DGX, LH, or PKI then come over to http://dailystocktracker.com/register/and sign up for your free customized reports today. Today, DailyStockTracker.com covers four Medical Laboratories and Research equities, which are VWR Corp. (NASDAQ: VWR), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE:
Radnor, Pennsylvania-based VWR Corp.'s stock finished Monday's session 0.03% higher at $32.98 with a total trading volume of 646,467 shares. Over the last month and the previous three months, the Company's shares have advanced 0.58% and 19.67%, respectively. Additionally, the stock has gained 31.76% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 5.78% and 18.20%, respectively. Moreover, shares of VWR Corp. , which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have a Relative Strength Index (RSI) of 73.00.
On May 23rd, 2017, VWR Corp. has published its 6th annual Sustainability Report. Detailing its global sustainability efforts, the report describes the Company's steady progress in addressing and improving the environmental, economic, and social impacts of its operations. This is the second year that the Company's report follows the Global Reporting Initiative G4 sustainability reporting guidelines. Your complete research report on VWR can be retrieved for free at:
Shares in Madison, New Jersey headquartered Quest Diagnostics Inc. climbed 0.44%, ending yesterday's session at $108.14 with a total trading volume of 848,450 shares. The stock has gained 2.36% in the past month, 9.05% in the previous three months, and 17.67% on an YTD basis. The Company's shares are trading 2.59% above their 50-day moving average and 15.39% above their 200-day moving average. Moreover, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 54.66.
On June 05th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $115 a share to $122 a share.
On June 12th, 2017, Quest Diagnostics announced that it has signed definitive agreements to acquire two laboratory businesses in Lewisville, Texas, with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. The two businesses, Med Fusion and Clear Point, together provide a full range of diagnostic services to physicians and provider networks. A free report on DGX is just a click away at:
Laboratory Corp. of America
On Monday, Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' ("LabCorp®") stock gained 0.80%, to close the day at $141.89. A total volume of 611,324 shares was traded. The Company's shares have advanced 2.63% in the last one month and 10.52% on an YTD basis. The stock is trading 0.60% above its 50-day moving average and 4.41% above its 200-day moving average. Additionally, shares of LabCorp®, which operates as an independent clinical laboratory company worldwide, have an RSI of 53.01.
On June 14th, 2017, LabCorp® announced that its Covance Drug Development (Covance) business will extend its capabilities in precision medicine by opening a dedicated, state-of-the-art companion diagnostics laboratory in Morrisville, North Carolina. The facility capitalizes on the Company's unique and industry-leading expertise and experience in companion diagnostics, combining end-to-end drug development through Covance with commercialization capabilities through LabCorp. Sign up for your complimentary research report on LH at:
Shares in Waltham, Massachusetts headquartered PerkinElmer Inc. ended the day 6.54% higher at $67.73. A total volume of 2.24 million shares was traded, which was above their three months average volume of 597,100 shares. The stock has gained 9.84% in the last one month, 18.53% in the previous three months, and 29.88% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 10.63% and 22.06%, respectively. Furthermore, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 80.20.
On June 19th, 2017, PerkinElmer announced that it has entered into a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that the former will acquire up to a 100% stake in EUROIMMUN. The total purchase price of the transaction, based on all outstanding shares being acquired, will be approximately $1.3 billion in cash. Sign up for your complimentary research report on PKI at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All